NEW YORK (GenomeWeb News) – Cellectricon and Fluxion Biosciences announced today they have settled a legal dispute dating back to 2009 in which Fluxion was accused of patent infringement.

Under the terms of the settlement, the firms will cross-license patents related to microfluidic cellular analysis.

Cellectricon and Fluxion said they will ask the US District Court for the Northern District of California to dismiss all claims that Cellectricon brought against Fluxion involving US Patent Nos. 7,390,650; 7,470,518; and 7,563,614.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.